
Treating neurodegeneration and neuronal injuries through the development of novel small molecule therapeutics

Headquarters
Location
Funding
Funding Numbers
Status
Status Info
Magnolia Neurosciences is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. Magnolia endeavors to make life-changing medicines for the benefit of patients and their families suffering from serious CNS diseases.
Magnolia was launched in 2017 with world class researchers at The University of Texas MD Anderson Cancer Center. The company also has a wholly owned subsidiary, Magnolia Tejas Corporation, based in Houston, Texas that is focused on developing a novel therapy for chemotherapy-induced neurological conditions.
“We chose to work with Accelerator because of the incredible team and the blue-chip caliber of its partners. Having partners as investors meant there was always someone at the table who understood our target pathway and could see how to create value beyond our initial indications.”
— Jim Ray, PhD, Director of Neurodegeneration Consortium, MD Anderson
“Accelerator’s ability to balance the risks inherent with real innovation against the reality that incremental progress won’t transform patient care is unique. The Accelerator’s team expertise provided a deep appreciation for the value of Magnolia’s work in addressing unmet clinical needs and helped pivot to develop an indication with tremendous potential for many cancer patients.”
— Phil Jones, PhD, Head of Drug Discovery, Institute for Applied Cancer Sciences (IACS), MD Anderson
PRINCIPAL INVESTIGATORS

